SEC and FDA Strengthen Collaboration Through New Agreement to Protect Market Integrity
The U.S. Securities and Exchange Commission and Food and Drug Administration sign a Memorandum of Understanding to enhance coordination and support their regulatory missions.

The SEC and FDA signed a Memorandum of Understanding to enhance cooperation and ensure market integrity, focusing on supporting their regulatory missions effectively.
In a move set to enhance regulatory effectiveness, the U.S. Securities and Exchange Commission (SEC) and the Food and Drug Administration (FDA) have formalized their cooperation through a recently signed Memorandum of Understanding (MOU). This agreement aims to foster seamless collaboration between the two agencies as they navigate overlapping concerns regarding market integrity and public protection.
The MOU establishes protocols for information sharing, joint efforts, and mutual assistance in matters where securities regulations intersect with public health regulations. By aligning their efforts, the SEC and FDA plan to improve oversight of markets affected by health-related innovations, which could include areas of growing interest to crypto creators and Web3 communities where finance and technology merge.
This partnership underscores a strategic approach to regulatory supervision, ensuring both consumer safety and transparent market practices. Industry observers note that enhanced agency cooperation can help maintain trust among investors and stakeholders who engage with increasingly complex products and services in the digital economy.
Method note
Information sourced from the official U.S. Securities and Exchange Commission press release published on August 31, 2026.
Sources
- U.S. Securities and Exchange Commission2026-08-31T18:24:32.000Z
